LOGIN-VSI
29.7.2020 14:32:11 CEST | Business Wire | Press release
HTG – Howell Technology Group, the specialised supplier of innovative IT and security solutions, today announced that it has signed a supplier agreement with Login VSI , the company dedicated to maximising the end-user experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200729005078/en/
Delivered through a customer-centric approach, HTG’s professional and trusted IT consulting services enables customers to operate sustainably and achieve efficiencies gained from transformation of their IT environments to modern, cloud-based workspaces.
This partnership will focus on the provision of specialist solutions and services as part of the ecosystem for Windows Virtual Desktop (WVD). Working closely with Microsoft as a Gold partner, HTG is already deploying WVD to some impressive accounts as a cloud-based, remote working solution. Adding Login VSI to this mix represents an opportunity for HTG to join forces with the market leader in synthetic user testing.
Kevin Howell, CTO, HTG said, “Sizing end-user compute solutions to deliver optimal user experience and performance can be complex. Using Login VSI allows us to deliver our services in a performant and efficient manner.”
For Login VSI, this partnership represents the opportunity to work with a highly regarded consultant. Using their specialised skills, HTG will be able to efficiently deploy Login Enterprise into their customer base – delivering to them application compatibility testing, load testing, as well as performance and availability testing in a single platform.
Since the onset of COVID, there has been an increased demand for enterprise IT organisations to support a global remote working model. Testing of a scaled-up remote infrastructure has therefore become critical. Login VSI provides comprehensive testing and validation of the entire technology stack, from the core to the endpoint. It maximises the scalability and availability of applications and virtual desktop environments, including cloud. Login Enterprise, Login VSI’s flagship product, enables enterprises to quickly identify potential performance or availability issues by measuring and comparing application load times and application responsiveness. It is this expertise that will provide added value to HTG’s services within the digital workspace and especially as part of the WVD ecosystem.
Graham Wight, CEO, HTG commented: “We are excited about the opportunity to work with Login VSI. With the recent shift in demand for technologies that enable the smooth and secure transition to remote working, there is a greater need for performance and availability testing. The addition of this service under the partnership can only enhance and add value to the services we provide our customers.”
“We are excited about the opportunity to work with HTG,” said Eric-Jan van Leeuwen, CEO of Login VSI. “Given the global shift to remote working, there is a greater need for performance and availability testing, in order to ensure business continuity. With HTG’s superior knowledge of the WVD market and the unrivalled experience they have, we believe this is the beginning of a long-lasting relationship.”
About HTG
HTG is a leading global IT solutions company offering a range of disruptive technologies and best in class products. We work closely with customers from a wide range of industries to enable efficiencies through transformation of their IT environments and help simplify the way our IT services are delivered to them. Our digital knowledge and expertise in the latest technologies enables us to help our customers define their digital vision and strategic roadmap, delivering real and impactful change.
For further information please visit www.htguk.com or contact us on 0191 481 3446 .
About Login VSI
Login VSI is the only solution in the market guaranteed to maximize the end-user experience for digital workspaces. We reduce risk and ensure business continuity by safeguarding application and desktop performance. We do this using synthetic users to automatically test and validate the impact of change in physical, virtual and cloud-based workspaces.
Our flagship product, Login Enterprise integrates application compatibility testing, load testing, as well as performance & availability testing into a single platform. Login Enterprise also includes standard “out-of-the-box” application template workloads. Login VSI has over 400 customers in 50 countries. For more information, visit www.loginvsi.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005078/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom